Cargando…
Emerging therapies for acute myeloid leukemia
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. However, various novel agents have demonstrated clinical ac...
Autores principales: | Saygin, Caner, Carraway, Hetty E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395764/ https://www.ncbi.nlm.nih.gov/pubmed/28420416 http://dx.doi.org/10.1186/s13045-017-0463-6 |
Ejemplares similares
-
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
por: Saygin, Caner, et al.
Publicado: (2018) -
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients
por: Saygin, Caner, et al.
Publicado: (2022) -
New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists
por: Carraway, Hetty, et al.
Publicado: (2004) -
Emerging Immunotherapy for Acute Myeloid Leukemia
por: Tabata, Rikako, et al.
Publicado: (2021) -
Emerging treatment options for patients with high-risk
myelodysplastic syndrome
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)